Introduction {#Sec1}
============

In patients with locally advanced head and neck cancer (LAHNC), both disease and treatment have a great impact on quality of life (QOL). Standard treatment for these patients is concomitant chemoradiotherapy, which induces severe acute and late toxicities. Common acute toxicities of chemoradiotherapy include mucositis, dermatitis, dysphagia, ototoxicity, and polyneuropathy. Late toxicity may consist of dysphagia sometimes with aspiration, odynophagia, xerostomia, fibrosis, and occasionally osteoradionecrosis \[[@CR1], [@CR2]\]. These toxicities negatively influence the QOL.

Induction chemotherapy, using docetaxel/cisplatin/5-fluorouracil (TPF), has been proposed as a means to improve outcome of patients with locally advanced head and neck cancer. There are only limited data on TPF followed by chemoradiotherapy using cisplatin. Although it is often stated that neo-adjuvant TPF is well tolerated, the effect of the total regimen, including the concomitant chemoradiation part, on health-related quality of life (HRQOL) has not been reported previously \[[@CR3], [@CR4]\]. HRQOL comprises physical and psychosocial functioning, social interaction and disease- and treatment-related symptoms. HRQOL was studied in LAHNC patients receiving neo-adjuvant TPF versus PF followed by radiotherapy alone, showing a trend towards a better HRQOL during treatment in favor of TPF \[[@CR5]\]. Other studies in LAHNC patients treated with chemotherapy and radiotherapy showed a pattern of decline of QOL and then return to baseline within 12 months after end of treatment \[[@CR6], [@CR7]\]. There are no published data of QOL in LAHNC patients treated with induction chemotherapy later than 12 months after end of treatment.

We conducted a randomized phase II feasibility study, the CONDOR study, on induction chemotherapy with TPF followed by cisplatin-based concomitant chemoradiotherapy in two different schedules \[[@CR8]\]. Sixty-two fit LAHNC patients started treatment with TPF. Of these patients, 56 were randomized to treatment with concomitant chemoradiotherapy with conventional chemoradiotherapy and cisplatin 100 mg/m^2^ three weekly (cis100 + RT) (27 patients) or concomitant CRT with accelerated radiotherapy with weekly cisplatin 40 mg/m^2^ (cis40 + ART) (29 patients). Ninety-six percent of the patients treated with cis100 + RT and 90% of the patients treated with cis40 + ART experienced grade 3 toxicity (on the Common Toxicity Criteria 3.0), whereas grade 4 toxicity occurred in 15 versus 14% of the patients. Most common grades 3--4 toxicity during TPF was febrile neutropenia (18%). During concomitant CRT, grades 3--4 toxicities were mucositis in 22 versus 57%, dysphagia in 26 versus 24%, and dehydration in 26 versus 14%, of patients with cis100 + RT and cis40 + ART, respectively. Both treatment schedules were proven not to be feasible, since the total planned dosage of cisplatin during the chemoradiotherapy could only be administered in 32% of all patients due to severe toxicity, leading to early termination of inclusion into the study. Despite high toxicity rates, efficacy was comparable with other studies using induction chemotherapy. Response rate after TPF was 61%, and 2-year overall survival was 77% in patients treated with cis100 + RT and 76% for those treated with cis40 + ART.

In this paper, we will focus on the HRQOL of patients treated in this phase II study with TPF induction chemotherapy followed by concomitant chemoradiotherapy, with emphasis on long-term follow-up outcome.

Methods {#Sec2}
=======

Trial design and participants {#Sec3}
-----------------------------

The CONDOR study was a randomized phase II feasibility study on induction chemotherapy with TPF followed by cisplatin-based concomitant chemoradiotherapy in two different schedules. In this study, fit LAHNC patients, stage III or IV with a WHO-performance score of 0--1 and age ≤ 65 years, were included. Patients were between 18 and 65 years of age, and adequate bone marrow, hepatic, and renal functions. Exclusion criteria were active alcohol addiction, admission for chronic obstructive pulmonary disease during the last 12 months, and weight loss of more than 10% during the last 3 months prior to study entry. Details on therapy schedules and toxicity registration and grading were published recently \[[@CR8]\].

QOL assessment {#Sec4}
--------------

QOL data were collected using the European Organization for Research and Treatment of Cancer (EORTC) QOL questionnaire (QLQ-C30) version 3.0 and the EORTC head and neck cancer module (HN-35) \[[@CR2], [@CR5], [@CR9]--[@CR11]\]. The EORTC QLQ-C30 contains a global HRQOL score, five functional scales (physical, role, cognitive, emotional, and social), three symptom scales (fatigue, nausea/vomiting, and pain), and six single-item scales (dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, and financial difficulties). The EORTC Head and Neck module, the EORTC QLQ-H&N35 has been specifically designed and validated for head and neck cancer patients \[[@CR11]\]. This is a 35-item questionnaire with seven symptom scales (pain, swallowing, senses, speech, social eating, social contact, and sexuality), six single-item scales (difficulties of teeth, mouth opening, dry mouth, sticky saliva, coughing, and feeling ill), and five items about the additional use of painkillers, nutritional supplements, and feeding tube and changes in body weight. All items were transformed to scales from 0 to 100, according to the EORTC scoring manual recommendations \[[@CR12]\]. A high score on functional scale represents a better level of functioning, whereas a high score on a symptom scale indicates more severe symptoms. Differences of at least 10 points (on a scale of 0--100) on a mean value of the HRQOL parameter were classified as clinically significant \[[@CR13]\]. Changes of ≥ 10 points are moderate, whereas changes of ≥ 20 points on a mean score are classified as large. The primary HRQOL analysis was based on preselected HRQOL scores: global HRQOL, pain, swallowing, speech, and coughing.

Patients completed the QOL questionnaires at baseline, after 2 cycles of TPF, before start of concomitant chemoradiotherapy (i.e.*,* after 2, 3, or 4 TPF cycles) and 1, 4, 8, 12, 18, and 24 months after the end of chemoradiotherapy.

Statistical analysis {#Sec5}
--------------------

HRQOL was a secondary endpoint of the CONDOR study; power analysis was calculated on the primary endpoint, which was feasible. Analyses were performed using SAS version 9.2 and SPSS version 20. Compliance rates were calculated as the number of forms received divided by the number of forms expected at each time point. Expected forms were from patients still alive at the given time point, regardless of disease state. Fishers' exact test was used to determine differences in compliance between the treatment arms. One-sided *t* test was used to compare the baseline quality-of-life results of the current study with the EORTC reference values.

For the primary analyses, we used an Unstructured Covariance Model to conduct separate repeated measures analyses for each HRQOL outcome \[[@CR14]\]. We included time, treatment, and the interaction between time and treatment as fixed factors in the linear mixed model. Time was treated as a categorical variable to allow the model to fit every possible pattern in time. The interaction between time and treatment was only defined after the start of the chemoradiotherapy. In addition, we added the baseline values of the dependent variables as possible significant covariates to the model. Residual plots from the mixed models were examined to assess model assumptions. All linear mixed model analyses were performed on all participants, including those with incomplete datasets. Differences between treatments at specific time moments were estimated from the mixed model. Two-tailed analyses were performed with a *p* value of 0.05.

Moreover, sensitivity analysis using the proportion of patients experiencing an improvement/worsening of more than 10 or 20 points in each selected scale was performed \[[@CR13]\].

Results {#Sec6}
=======

Participants {#Sec7}
------------

Patient characteristics are shown in Table [1](#Tab1){ref-type="table"}. A CONSORT diagram is added as eFig. [1](#Fig3){ref-type="supplementary-material"}.Table 1Patient characteristicsTotal = 62 ptsCis100 + RT = 27 ptsCis40 + ART = 29 pts*N* (%)*N* (%)*N* (%)Sex Male50 (80.6)17 (63)27 (93.1) Female12 (19.4)10 (37)2 (6.9)Age (years) Mean53.454.053.2 Range27--6532--6527--64WHO performance status 049 (79)23 (85.2)23 (79.3) 113 (21)4 (14.8)6 (20.7)Tumor site Oral cavity12 (19.4)4 (14.8)6 (20.7) Oropharynx37 (59.7)18 (66.7)16 (55.2) Hypopharynx8 (12.9)3 (11.1)5 (17.2) Larynx5 (8.1)2 (7.4)2 (6.9)Disease stage III5 (8.1)2 (7.4)3 (10.3) IV57 (91.9)25 (92.6)26 (89.7)Abbreviations: pts, patients; Cis100 + RT, cisplatinum 100 mg/m^2^ with conventional radiotherapy; Cis40 + ART, cisplatinum 40 mg/m^2^ with accelerated radiotherapy

QOL: compliance {#Sec8}
---------------

Data of all patients were included in this analysis. Compliance to the questionnaires was 94% at baseline, 71% after 2 TPF, 70% before start of chemoradiotherapy, 61% after chemoradiotherapy, 63% after 4 months, 66% after 12 months, 68% after 18 months, and 62% after 24 months of follow-up. Compliance was significantly lower in patients treated with cis40 + ART at 4 months after end of treatment, 45 versus 81%, respectively (*p* = 0.006). At all other time points compliance between the two treatment arms was similar.

QOL baseline scores {#Sec9}
-------------------

Baseline QOL scores were compared with the reference values of head and neck cancer patients, stage III--IV diseases ([eTable 1](#MOESM2){ref-type="media"}), provided by the EORTC \[[@CR15]\]. All EORTC head and neck reference data are based on pretreatment HRQOL. A clinically and statistically significant difference in baseline scores of our patients compared with the EORTC reference values was found on global HRQOL (75.3 versus 63.3, *p* \< 0.001) and physical function (92.0 versus 81.2, *p* \< 0.001), and on the symptom scores sexuality (14.2 versus 32.2, *p* \< 0.001), dry mouth (15.3 versus 31.1, *p* \< 0.001), sticky saliva 19.5 versus 32.4, *p* \< 0.001), coughing (18.6 versus 34.9, *p* \< 0.001), feeling ill (12.4 versus 21.7, *p* = 0.003), and feeding tube (5.1 versus 18.3, *p* \< 0.001), in favor of the patients in our study. This indicates that in terms of QOL a relatively favorable (i.e., fit) patient group was selected for this study.

QOL during TPF {#Sec10}
--------------

Global HRQOL decreased non-significantly after 2 TPF (70.1) and even more after the end of TPF (64.0) (Table [2](#Tab2){ref-type="table"}; Fig. [1](#Fig1){ref-type="fig"}). Pain and swallowing problems both decreased with more than 10 points after 2 TPF, but both increased before start of chemoradiotherapy (Table [2](#Tab2){ref-type="table"}; Fig. [2](#Fig2){ref-type="fig"}). Speech problems and coughing improved non-significantly after two TPF, but deteriorated at the end of TPF (Table [2](#Tab2){ref-type="table"}; Fig. [2](#Fig2){ref-type="fig"}).Table 2Mean scores over time at baseline, after two TPF, after chemoradiotherapyBaseline (59/62)After 2 TPF (42/59)After CRT cis100 + RT (18/27)After CRT cis40 + ART (16/29)Difference between groups CRT (*p* value)MeanSDMeanSDMeanSDMeanSDEORTC QLQ-30 Global health status75.319.770.111.544.911.946.112.00.85 Physical function92.015.180.5^a^11.261.011.558.411.60.60 Role function86.123.859.6^a^15.245.015.936.016.20.32 Emotional function74.721.484.9^a^12.384.912.377.612.80.61 Cognitive function91.715.287.618.070.218.267.418.30.61 Social function87.518.179.614.566.414.967.115.10.91 Fatigue20.820.935.7^a^10.650.611.260.811.50.97^b^ Nausea/vomiting2.58.68.65.430.96.037.66.30.20 Pain25.629.711.0^a^14.633.815.049.215.30.043^b^ Dyspnoea6.714.79.011.216.011.419.911.60.45 Insomnia25.027.918.111.627.612.127.512.30.99 Appetite loss17.227.822.817.550.218.162.218.30.19^b^ Constipation12.224.511.45.620.66.532.06.90.08^b^ Diarrhea2.28.412.9^a^8.88.19.110.59.30.63 Financial problems13.326.211.416.98.317.225.017.30.011^b^EORTC QLQ-H&N 35 Pain27.222.514.5^a^11.938.112.255.712.30.003^b^ Swallowing24.925.19.7^a^10.843.311.359.911.40.0101^b^ Senses10.521.021.7^a^15.245.015.647.315.80.74 Speech18.121.310.97.927.18.544.88.70.004^b^ Social eating21.926.015.314.341.414.639.914.80.82 Social contact5.614.97.96.812.97.09.57.00.29 Sexuality14.225.233.3^a^19.453.920.055.020.10.90 Teeth19.127.26.3^a^14.110.414.515.214.90.53 Opening mouth25.434.113.3^a^16.827.217.331.517.40.58 Dry mouth15.324.225.3^a^18.244.418.756.818.90.14^b^ Sticky saliva19.531.220.520.257.520.666.320.80.32 Coughing18.625.014.412.331.812.845.313.00.076^b^ Feeling ill12.421.419.826.648.132.847.932.10.98 Pain killers61.049.241.2^a^24.995.625.983.526.30.40^b^ Nutritional support31.046.719.7^a^18.583.019.666.020.00.20^b^ Feeding tube5.122.24.815.752.316.685.017.00.003^b^ Weight loss43.950.015.2^a^14.681.316.133.317.10.0009^b^ Weight gain17.938.650.8^a^21.826.323.419.324.60.70Abbreviations: cis100 + RT, cisplatin 100 mg/m^2^ on days 1, 22, and 43 in combination with conventional radiotherapy; cis40 + ART, cisplatin 40 mg/m^2^ weekly in combination with accelerated radiotherapy; EORTC, European Organization for Research and Treatment of Cancer; QLQ-C30, Quality of Life Questionnaire C30; QLQ-HN-35, Head and Neck Cancer-Specific Module^a^Clinically significant difference (10 points or more) after 2 TPF compared to baseline^b^Clinically significant difference (10 points or more) between treatment arms after CRT Fig. 1Mean Global Health Scores over time by treatment arm Fig. 2Mean symptom scores over time by treatment arm: **a** pain, **b** coughing, **c** speech problems, and **d** swallowing problems

QOL: differences between treatment arms during chemoradiotherapy and changes over time {#Sec11}
--------------------------------------------------------------------------------------

Global HRQOL decreased during chemoradiotherapy, equally in both arms (Table [2](#Tab2){ref-type="table"}; Fig. [1](#Fig1){ref-type="fig"}). Four months after end of treatment, global HRQOL increased and it was restored to baseline levels within 12 months after end of treatment. Beyond 12 months however, patients treated with cis100 + RT had a higher score than the patients treated with cis40 + ART, albeit not significant. Twenty-four months after end of treatment global HRQOL was equal in both arms (Table [3](#Tab3){ref-type="table"}). Pain, swallowing problems, speech problems and coughing all worsened during chemoradiotherapy. A clinically and statistically significant difference between the treatment arms at end of treatment was found in all these symptom scores in favor of the patients treated with cis100 + RT (Table [2](#Tab2){ref-type="table"}; Fig. [2](#Fig2){ref-type="fig"}). In both treatment arms, pain, swallowing problems, and speech problems recovered to baseline level 4 months after treatment. There were no differences in mean scores of pain, swallowing problems, speech problems, and coughing between the treatment arms at 12 and 24 months after end of treatment (Table [3](#Tab3){ref-type="table"}).Table 3Mean scores over time at baseline, and after 1 and 2 years after treatment1-year follow-up cis 100 + RT1-year follow-up cis 40 + ARTDifference between groups (*p* value)2-year follow-up cis 100 + RT2-year follow-up cis 40 + ARTDifference between groups (*p* value)MeanSDMeanSDMeanSDMeanSDEORTC QLQ-30 Global health status84.09.971.424.10.07^a^80.616.476.223.80.64 Physical function91.310.785.116.10.2292.87.888.611.40.35 Role function87.215.473.537.70.19^a^83.322.573.830.20.44 Emotional function91.010.578.624.90.09^a^83.325.188.116.60.66 Cognitive function93.68.481.325.70.09^a^88.916.469.033.90.19^b^ Social function91.012.981.329.70.2893.113.288.115.90.47 Fatigue16.217.923.524.50.3722.221.728.631.30.61 Nausea/vomiting0.00.03.9211.10.160.00.07.118.90.36 Pain5.110.516.730.00.16^a^8.316.77.118.90.89 Dyspnoea2.69.213.720.60.08^a^2.89.69.516.30.35 Insomnia2.69.217.620.80.02^a^11.121.714.317.80.75 Appetite loss7.720.017.626.70.255.613.014.326.20.44 Constipation0.00.011.820.20.046^a^5.613.00.00.00.17 Diarrhea0.00.02.18.30.330.00.04.812.60.36 Financial problems10.316.014.629.70.620.00.04.812.60.36EORTC QLQ-H&N 35 Pain8.310.814.717.30.237.410.512.511.80.33 Swallowing4.58.112.715.90.084.98.311.512.50.17 Senses17.917.317.621.61.0016.726.612.57.70.62 Speech4.39.713.720.60.110.93.26.98.30.08 Social eating10.911.019.124.60.196.912.717.722.00.18^b^ Social contact0.51.87.314.80.230.61.91.74.70.47 Sexuality12.516.127.826.50.09^a^11.117.913.916.40.75 Teeth2.69.214.627.10.11^a^5.613.08.323.60.74 Opening mouth12.816.915.720.80.6913.922.320.824.80.52 Dry mouth43.621.049.029.10.5833.324.641.723.60.46 Sticky saliva17.922.031.328.50.18^a^16.722.537.521.40.05^b^ Coughing10.316.015.723.90.498.315.18.315.41.00 Feeling ill2.69.217.631.40.08^a^8.320.74.211.80.61 Pain killers7.727.723.543.70.24^a^16.738.925.046.30.67 Nutritional support15.437.623.543.70.600.00.012.535.40.35^b^ Feeding tube0.00.05.924.30.390.00.012.535.40.35^b^ Weight loss0.00.025.044.70.04^a^8.328.912.535.40.78 Weight gain46.251.931.347.90.43^a^41.751.525.046.30.47^b^Abbreviations: cis100 + RT, cisplatin 100 mg/m^2^ on days 1, 22, and 43 in combination with conventional radiotherapy; cis40 + ART, cisplatin 40 mg/m^2^ weekly in combination with accelerated radiotherapy; EORTC, European Organization for Research and Treatment of Cancer; QLQ-C30, Quality of Life Questionnaire C30; QLQ-HN-35, Head and Neck Cancer-Specific Module^a^Clinically significant difference (10 points or more) 1 year after treatment between treatment arms^b^Clinically significant difference (10 points or more) between treatment arms after 2 years

Other HRQOL scales {#Sec12}
------------------

All other HRQOL items were analyzed on an exploratory basis. Patients treated with cis40 + ART scored clinically and statistically significantly worse on feeding tube dependence after CRT but significantly better on nutritional support and use of painkillers. Patients treated with cis100 + RT scored clinically and statistically significant worse on weight loss.

Moreover, a clinically significant difference (\> 10 points) was found for fatigue, appetite loss, constipation, and dry mouth in favor of cis100 + RT.

Furthermore, after 2 years follow-up patients treated with cis100 + RT had clinically significant (\> 10 points) better cognitive function and less sticky saliva compared with patients treated with cis40 + ART. Patients treated with cis40 + ART scored clinically significant worse on nutritional support and feeding tube than patients in arm cis100 + RT (Table [3](#Tab3){ref-type="table"}).

Sensitivity analyses {#Sec13}
--------------------

The proportion of patients experiencing an improvement or worsening of 10 or 20 points on the selected scales between baseline and end of chemoradiotherapy were compared between the treatment arms. These analyses showed the same trend of more pain in patients treated with cis40 + ART compared with cis100 + RT (Table [4](#Tab4){ref-type="table"}). Moreover, a higher percentage of patients experienced a worsening in speech and swallowing problems in the group treated with cis40 + ART, whereas more patients experienced improvement in the group treated with cis100 + RT (Table [4](#Tab4){ref-type="table"}).Table 4Sensitivity analysis: proportion of patients experiencing improvement/worsening of selected scales after chemoradiotherapy compared with baselineCis100 + RT (*N* = 27) N (%)Cis40 + ART (*N* = 29) N (%)*p* value for differenceGlobal qualiy of life^a^ ≥ 16.6 points worsening15 (83.3)10 (71.4)0.669 ≥ 25 points worsening13 (72.2)8 (57.1)0.465 ≥ 16.6 points improvement0 (0)1 (7.1)0.437 ≥ 25 points improvement0 (0)01.00Coughing^b^ ≥ 33.3 points worsening10 (58.8)8 (57.1)1.00 ≥ 33.3 points improvement3 (17.6)3 (21.4)1.00Pain^c^ ≥ 11.1 points worsening8 (47.1)12 (85.7)0.057 ≥ 22.2 points worsening7 (41.2)11 (78.6)0.067 ≥ 11.1 points improvement4 (23.5)2 (14.3)0.664 ≥ 22.2 points improvement2 (11.8)1 (7.1)1.00Speech problems^d^ ≥ 11.1 points worsening8 (47.1)10 (71.4)0.275 ≥ 22.2 points worsening6 (35.3)8 (57.1)0.289 ≥ 11.1 points improvement5 (29.4)2 (14.3)0.412 ≥ 22.2 points improvement4 (23.5)2 (14.3)0.664Swallowing^e^ ≥ 11.1 points worsening12 (70.6)11 (78.6)0.698 ≥ 22.2 points worsening11 (64.7)10 (71.4)1.00 ≥ 11.1 points improvement4 (23.5)2 (14.3)0.664 ≥ 22.2 points improvement3 (17.6)1 (7.1)0.607Abbreviations: cis100 + RT, cisplatin 100 mg/m^2^ on days 1, 22, and 43 in combination with conventional radiotherapy; cis40 + ART, cisplatin 40 mg/m^2^ weekly in combination with accelerated radiotherapy^a^Global QoL score may take all values from 0 to 100 distance by 8.3 points (0, 8.3, 16.6, and so on). A shift of more than 10 points means a shift of 16.6 points or more. A shift of more than 20 points means a shift of 25 points or more^b^Coughing score may take all values from 0 to 100 distance by 33.3 points (0, 33.3, 66.6, and so on)^c^Pain score may take all values from 0 to 100 distance by 2.8 points^d^Speech score may take all values from 0 to 100 distance by 5.5 points^e^Swallowing score may take all values from 0 to 100 distance by 2.8 points

Discussion {#Sec14}
==========

HRQOL was assessed as secondary endpoint of the randomized phase II CONDOR study in patients with locally advanced head and neck cancer treated with TPF induction chemotherapy followed by cisplatin 100 mg/m^2^ with conventional radiotherapy versus cisplatin 40 mg/m^2^ with accelerated radiotherapy. Our study patients had a clinically and statistically significant better global HRQOL and physical function compared with the EORTC reference values for head and neck cancer patients with stage III-IV disease, which data were obtained during standard treatment \[[@CR15]\]. Global HRQOL in our patients was also better than the patients included in the EORTC 24971/TAX 323 study \[[@CR5]\]. This is a reflection of our selection criteria to include only very fit LAHNC patients, i.e., no admissions for COPD in the past year, WHO 0--1, no weight loss more than 10% in the past 3 months, no active alcohol addiction, and adequate bone marrow, liver, and kidney functions. Despite the excellent clinical condition of our patients at baseline reflected by the good global HRQOL, both treatment schedules were shown not feasible \[[@CR8]\].

Global HRQOL declined during TPF and more during chemoradiotherapy, without any difference between the two treatment arms. The declining global HRQOL is in contrast with the results of the EORTC 24971/TAX 323 study, where global HRQOL improved during TPF \[[@CR5]\]. In that study however, baseline global HRQOL was significantly lower than in our study (61.2 versus 75.3, respectively, *p* \< 0.001). After 2 cycles of TPF though, global HRQOL scores in the CONDOR and TAX 323 cohorts were comparable, 70.1 and 69.3, respectively. However, before start with CRT the global HRQOL scores of the CONDOR cohort decreased further (64.0) while the TAX 323 cohort remained stable (70.7; *p* \< 0.05). This is in agreement with Tribius et al. who reported a significant greater deterioration in global HRQOL in patients with the highest baseline scores \[[@CR16]\].

Global HRQOL restored to baseline levels within 12 months after end of treatment and remained at that level after 24 months. This is in line with other QOL in head and neck cancer studies \[[@CR6], [@CR9], [@CR17]\] and is not very satisfying, because an improvement in Qol is desirable in cured patients. This pattern of no improvement in quality of life could be hypothetically caused by substitution of tumor-associated complaints at presentation by therapy sequelae-associated complaints leading to high symptom scores after the end of treatment \[[@CR18]\]. Other studies concerning induction chemotherapy in head and neck cancer did not include QOL analysis \[[@CR19]--[@CR21]\].

In contrast to the declining global HRQOL scores, we found improvement of symptom scores, especially for pain and swallowing problems during TPF. This is in line with the results of the EORTC 24971/TAX 323 study \[[@CR5]\] and presumably reflects tumor response, which is consistent with our efficacy results; 62% of the patients had partial or complete responses after TPF. The improvement in pain and swallowing problems did not lead to better global health. Probably, the increase of other symptom scores such as fatigue, constipation, and feeling ill plays a role in declining global health score.

Patients in the CONDOR study showed differences in physician rated toxicity scores of mucositis and dysphagia between the two treatment arms, showing more grades 3 and 4 mucositis in the patients treated with cis40 + ART (59 versus 26%). The differences in symptom scores on speech problems, swallowing problems and pain in favor of the patients treated with cis100 + RT are in line with this. As described earlier, the difference in mucositis can be explained by the toxicity caused by accelerated radiotherapy and the weekly radio-sensitizing effect of cisplatin \[[@CR8], [@CR22]\]. High toxicity rates were observed with this treatment schedule, causing increasing symptom scores and decreasing global HRQOL during treatment. Despite this, all symptom scores in both treatment arms returned to baseline level at 12 months after end of treatment.

The main limitations of this study are the relatively small patient population and the difference in compliance between the two treatment arms at 4 months after chemoradiotherapy namely 45% versus 81% in cis40 + ART and cis100 + RT respectively. This difference in compliance rate at 4 months could have led to selection bias, since patients treated with cis40 + ART experienced more toxicity during chemoradiotherapy and had worse symptom scores. Assuming that the patients treated with cis40 + ART who had more symptoms were less likely to return the questionnaires, possibly the QoL scores at 4 months for this group are overestimated.

Our study has several strengths. It has a randomized design, and it is the first study reporting on QOL in patients treated with induction chemotherapy followed by concomitant cisplatin-based chemoradiotherapy. Because we used standard and validated questionnaires, comparison of our results with other studies in locally advanced head and neck cancer is possible. Overall compliance in our study was high, with more than 60% returned questionnaires during treatment as well as after 1 and 2 years after end of treatment. This is much higher than the compliance rate of 45% after 9 months in the EORTC 24971/TAX 323 study \[[@CR5]\].

In summary, in our patients with locally advanced head and neck cancer, we found high baseline HRQOL scores. However, despite this initial high global health score, reflecting the good condition of the patients participating in the CONDOR study, both chemoradiation treatment schedules after prior TPF chemotherapy were shown not feasible. Especially patients treated with cis40 + ART experienced high rates of grades 3 and 4 mucositis and consequently high symptom scores (pain, swallowing problems, and feeding tube dependence) during treatment.

Importantly, global health and all the symptom scores restored to baseline levels within 12 months after end of treatment in both arms and remained at that level at 2 years of follow-up after end of treatment. This is remarkable given the impressive toxicity the patients have gone through, and important with regard to the quality of the survivorship of these patients who presented with such advanced localized head and neck carcinomas.
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